Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 4Carcinoma, Non-Small-Cell Lung 3Myelodysplastic Syndromes 2Metastatic Solid Tumors 2Melanoma 2Solid Tumors 1Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer 1Recurrence 1Prostate Cancer Patients Undergoing Radical Prostatectomy 1Neoplasms 1Neoadjuvant Treatment for Locally Advanced Cervical Cancer 1Myeloproliferative Disorders 1Lymphoma 1Leukemia, Myelomonocytic, Chronic 1Glioma 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Breakthrough Pain 1Biliary Tract Neoplasms 1Advanced Malignant Neoplasm 1

Interventions

Fentanyl 7Morphine 2Ultracet 1Passive Cutaneous Anaphylaxis 1Methadone 1Infusions, Intravenous 1Gastrostomy 1Administration, Sublingual 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breakthrough Pain × Infusions, Intravenous × Clear all
NCT05053308 2023-08-07

Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement

Seoul National University

Phase NA Withdrawn

Cancer Pain, Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡